Handa Pharmaceuticals (ROCO:6620) Treasury Stock: NT$-561 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6620 Handa Pharmaceuticals Inc ROCO:6620
86 GF Score
Price NT$86.80
GF Value NT$109.18
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Handa Pharmaceuticals Treasury Stock?

Handa Pharmaceuticals ROCO:6620 -6.57% 86 Treasury Stock is NT$-561 Mil as of Jun. 2026. GuruFocus rates ROCO:6620 with a GF Score™ of 86/100 and a GF Value™ of NT$109.18 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Treasury stock is the portion of shares that a company keeps in their own treasury. Handa Pharmaceuticals's treasury stock for the quarter that ended in Jun. 2026 was NT$-561 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Handa Pharmaceuticals Treasury Stock Historical Data

* Premium members only.

The historical data trend for Handa Pharmaceuticals's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Handa Pharmaceuticals Treasury Stock Chart

Handa Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Treasury Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -56.52 -114.40

Handa Pharmaceuticals Quarterly Data
Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Treasury Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -114.40 -114.40 -114.40 -265.14 -560.78
ROCO:6620
86GF Score
Handa Pharmaceuticals Inc ROCO:6620
Treasury Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Handa Pharmaceuticals Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Frequently Asked Questions Learn more about Treasury Stock →
What does a Treasury Stock of NT$-561 Mil mean?
Handa Pharmaceuticals (ROCO:6620) has a Treasury Stock of NT$-561 Mil as of Jun. 2026. Treasury stock is a contra-equity item that records the amount of stock not issued to shareholders. View historical data for Handa Pharmaceuticals and its competitors.
Is Handa Pharmaceuticals' Treasury Stock too high?
Handa Pharmaceuticals' current Treasury Stock is NT$-561 Mil. Overall, Handa Pharmaceuticals has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Handa Pharmaceuticals' Treasury Stock compare to ZTS?
Handa Pharmaceuticals' Treasury Stock of NT$-561 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Treasury Stock for a Drug Manufacturers company?
A good Treasury Stock depends on the Drug Manufacturers industry context. However, Treasury Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Treasury Stock mean?
A high Treasury Stock can signal that a stock is expensive relative to its fundamentals. Treasury stock is a contra-equity item that records the amount of stock not issued to shareholders. View historical data for Handa Pharmaceuticals and its competitors. Handa Pharmaceuticals's current Treasury Stock is NT$-561 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Handa Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Handa Pharmaceuticals (ROCO:6620) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$109.18, compared to a current price of NT$86.80 — trading 20.5% below its estimated fair value. The current Treasury Stock is NT$-561 Mil. Handa Pharmaceuticals' overall GF Score™ is 86/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Treasury Stock calculated?
Treasury Stock is calculated from a company's financial statements. For Handa Pharmaceuticals (ROCO:6620), the current Treasury Stock is NT$-561 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Handa Pharmaceuticals (ROCO:6620) Overvalued in 2026?

Based on GuruFocus' analysis, Handa Pharmaceuticals stock appears to be undervalued. The current stock price of NT$86.80 is trading 20.5% below its estimated GF Value™ of NT$109.18. GuruFocus considers Handa Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for ROCO:6620:

  • Treasury Stock: NT$-561 Mil
  • GF Value™: NT$109.18 vs. price of NT$86.80 (20.5% below fair value)
  • GF Score™: 86/100 with 2 warning signs

No single metric tells the full story. See the ROCO:6620 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Handa Pharmaceuticals Business Description

Address Nanke 3rd Road, 3F-1,3F-2, No.23, Xinshi Dist, Tainan, TWN, 74147
Handa Pharmaceuticals Inc is a Taiwan-based specialty pharmaceutical company. It is engaged in the development of niche drugs. The company focuses on the development of high-barrier/patentable niche products.
86GF Score

Get the complete analysis for ROCO:6620

Treasury Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$86.80
Price
NT$109.18
GF Value